In March 2021, an elevated concentration of CA 19.9 (1177.95 U/ml) was detected in a 71-year-old patient during a routine check-up. The remaining biochemical parameters, including the CEA marker, and the blood count, were within normal limits. The patient remained asymptomatic. In the previous year (January 2020), the patient underwent a right-sided hemicolectomy as a curative treatment for partially mucinous G2 adenocarcinoma (pT4bN0R0LV0). Based on an elevated concentration of CA 19.9, suspicion was raised regarding primary biliary carcinoma or dissemination of CRC. An abdominal and pelvic computed tomography (CT) in May 2021 revealed a hepatic lesion, necessitating differentiation between cholangiocarcinoma and atypical hemangioma (fig. 1 A–C). After 22 months, a follow-up CT did not confirm the presence of malignancy and stable CT picture (fig. 1 D). Concurrently, CA 19.9 concentrations, initially elevated in multiple measurements, exhibited a decrease, returning to normal levels by June 2021. At present, the patient remains asymptomatic, with imaging and biochemical test results within the normal range. This clinical case shows that a CA 19.9 marker concentration test is not intended for screening purposes, but is useful for monitoring the treatment and follow-up of patients with gastrointestinal malignancies who demonstrated elevated levels prior to initiating therapy. In addition, a high concentration of Ca 19.9 is not a pathognomonic symptom of gastrointestinal cancers. Numerous non-neoplastic conditions may manifest with elevated levels of CA 19.9 [1, 2].
Pictures in oncology
NOWOTWORY Journal of Oncology
2024, volume 74, number 3, 238
DOI: 10.5603/njo.99118
© Polskie Towarzystwo Onkologiczne
ISSN 0029–540X, e-ISSN: 2300-2115
www.nowotwory.edu.pl
High CA 19.9 concentration as a diagnostic dilemma in gastrointestinal cancer survivors
How to cite:
Grela-Wojewoda A, Puskulluoglu M, Anioł J, Ziobro M. High CA 19.9 concentration as a diagnostic dilemma in gastrointestinal cancer survivors. NOWOTWORY J Oncol 2024; 74: 238.
This article is available in open access under Creative Common Attribution-Non-Commercial-No Derivatives 4.0 International (CC BY-NC-ND 4.0) license, allowing to download articles and share them with others as long as they credit the authors and the publisher, but without permission to change them in any way or use them commercially.
- Dembińska-Kieć A, Naskalski JW, Solnica B. Diagnostyka laboratoryjna z elementami biochemii klinicznej. Edra Urban & Partner 2017.
- Vogel A, Cervantes A, Chau I, et al. Correction to: “Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up”. Ann Oncol. 2019; 30(5): 871–873, doi: 10.1093/annonc/mdy510, indexed in Pubmed: 30715202.